AstraZeneca discontinues Phase III trials of Stabilizer-CKD and Dialize-Outcomes
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Almost 300 million people globally have chronic hepatitis B
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Subscribe To Our Newsletter & Stay Updated